Accure Therapeutics
R&D pharma dedicated to developing innovative medicines to treat patients suffering from Central nervous system diseases
R&D pharma dedicated to developing innovative medicines to treat patients suffering from Central nervous system diseases
Accure Therapeutics is a R&D pharma company with a focus on developing innovative medicines for patients suffering from severe central nervous system diseases. The company's mission is to impede the degeneration and death of dysfunctional neurons and their glial support system. By developing Disease Modifying Therapies, Accure Therapeutics aims to correct pathological changes responsible for diseases such as Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease, and Epilepsy. Since its founding in 2020 in Spain, the company has attracted $1.60M in its latest investment round, led by the Michael J. Fox Foundation and the Luxembourg National Research Fund. With a strong industry presence in Biotechnology, Health Care, and Health and Wellness, Accure Therapeutics is positioned to make significant contributions in treating central nervous system diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Select | $1.60M | 2 | Michael J. Fox Foundation, Luxembourg National Research Fund | 07 Apr 2025 |
| Series A | €7.60M | 3 |
|
26 May 2020 |
We care about your data, and we'd love to use cookies make your experience better.
